The primary benefit of the ROMA algorithm is its ability to improve the accuracy of ovarian cancer diagnosis. By combining HE4, CA-125, and menopausal status, ROMA provides a more nuanced risk assessment than either biomarker alone. This helps in better stratifying patients into low-risk and high-risk categories, potentially reducing unnecessary surgeries and focusing attention on those who need further investigation.
